Netflix, Inc. (NASDAQ:NFLX) shot up more than 10% in pre-market trading to $108.75 after the online video streaming company posted second quarter earnings. Netflix posted $1.64 billion in revenue, right in-line with expectations and up from $1.34 billion in the same quarter of last year. The company posted EPS of $0.06 after adjusting for the 7-1 stock split, which would have been $0.42 using the pre-split data. Furthermore, the company surpassed 65 million members, adding a record 3.3 million members this quarter compared to 1.7 million members in the quarter prior. Netflix also posted a record amount of original content and does not have plans to slow down. According to the 22 analysts polled by TipRanks in the past 3 months, 18 are bullish on the stock, 2 are neutral, and 2 are bearish.
Amira Nature Foods Ltd (NYSE:ANFI) shares increased 7.56% in pre-market trading to $12.24 after the company released fourth quarter 2015 results and full year fiscal 2015 results. The company posted quarterly revenue of $226.8 million, topping the analyst consensus of $217.26 million and marking a 21.6% year-over-year increase. Adjusted EPS for the quarter was $0.52, coming in ahead of the analyst consensus of $0.49 and marking a 10.6% year-over-year increase. Revenue for the full year was $699.4 million, marking a 27.8% year-over-year increase. According to TipRanks, 1 analyst has been bullish on the stock in the past year with a $17 price target, marking a nearly 50% potential upside from where shares are currently trading.
Synthetic Biologics Inc (NYSEMKT:SYN)shares plummeted more than -19% in pre-market trading to $3.04, after the company announced a public offering of common stock. The company will use proceeds from the offerings to fund clinical trials, research and development, and investments among other needs. Synthetic Biologics’ Phase 2 clinical candidates currently include SYN-004 for C. difficile infection and SYN-010 for irritable bowel syndrome. Both analysts polled by TipRanks in the past 3 months are bullish on the stock.
Garmin Ltd. (NASDAQ:GRMN) shares sunk more than -10% in pre-market trading to $41.44 after the company posted preliminary second quarter earnings that fell below estimates. Garmin expects to post Q2 revenue between $770 million and $775 million, compared to the analyst consensus of $773 million. The company expects to post diluted EPS between $0.70 and $0.72, also falling below the analyst consensus of $0.91. The company also warned of decelerating sales in the fitness segment, attributing the sequential slowdown to “the strong channel fill in the second quarter 2014.” Garmin will formally announce second quarter earnings before the market opens on July 29. According to the 4 analysts polled by TipRanks in the past 3 months, 1 is bullish on the stock, 2 are neutral, and 1 is bearish. The average 12-month price target is $48.67, marking a 4.9% potential upside from where shares are currently trading.